Entrada Therapeutics
Update in progressTRDA (NasdaqGM)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
Entrada Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on delivering medicines that target intracellular proteins once considered inaccessible. Its platform uses an Endosomal Escape Vehicle to enable intracellular delivery, with a pipeline of genetic medicines aimed at neuromuscular and inherited retinal diseases. Preclinical programs include ENTR-601-44, ENTR-601-45 and VX-670. Incorporated in 2016 and based in Boston, it was formerly CycloPorters, Inc., changing its name in 2017.
Company score
- Sentiment
- 0.05
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.20
- Governance
- -0.13
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.03
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.04
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Company
- MarketNasdaqGM (NGM)
- LocationUnited States
- CEOMr. Dipal Doshi
- Founded2016
- Employees152
- Websitewww.entradatx.com
Identifiers
- ISINUS29384C1080
- FIGIBBG00MTSMC16
- CUSIP29384C108
- CIK0001689375